Document is current
Any future updates will be listed below
-
Authors
Areklett, E. W.
Hagen, B. I.
Stubberud, J.
Fagereng, E.
Andersson, S.
Lindemann, K.
-
Funding
Funding for this research was provided by:
University of Oslo
- License Information
-
More Information
Article History
Received: 2 May 2024
Accepted: 22 October 2024
First Online: 22 November 2024
Declarations
:
: The study is approved by the Regional Committee for Medical Research Ethics in South-Eastern Norway (2018/2242 and 267384). Approval is also obtained from the institutional review board at the Department of Gynecological Oncology, Oslo University Hospital (OUH), and the OUH data inspectorate.
: All participants signed a written informed consent prior to inclusion.
: Author E.W.A has received speaker and consultant honoraria from Pfizer. Author K.L has served on advisory boards for Eisai, MSD, Nycode, Astra Zeneca and GSK, received speaker honoraria from Eisai, and grants from GSK (paid to institution). Author E.F, J.S, B.I.H, and S.A have no relevant financial or non-financial interests to disclose.
